Pharmacy Medical News about Diabetic Neuropathies Cannabis Sativex

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

Anti-CD20 Antibody Granted Accelerated Approval for CLL

Roberta Buell, MBA
Congress Proposes SGR Fix

Dorothy J. Schirf, MD

Technology Advances

Strategic Therapy of Glioblastoma Gains Ground

Sara Hartley

Cancer Science

HPV Prevalence at Root of Racial Disparity in Head and Neck Cancer

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A Randomised Placebo Controlled Double Blind Clinical Trial of Cannabis Based Medicinal Product (Sativex) in Painful Diabetic Neuropathy: Depression is a Major Confounding Factor
Diabetes Care, 10/09/09

Selvarajah D et al. – This first ever, trial assessing the efficacy of cannabis has shown it to be no more efficacious than placebo in painful–DPN. Depression was a major confounder and may have important implications for future painful–DPN trials.

Methods

In this randomized controlled trial, 30 subjects with painful–DPN received daily Sativex or placebo.
Primary outcome measure was change in mean daily pain scores and secondary outcome measures included quality of life assessments.

Results

There was significant improvement in pain scores in both groups but mean change between groups was not significant.
There were no significant differences in secondary outcome measures.
Patients with depression had significantly greater baseline pain scores that improved regardless of intervention.

<< Previous
Oxcarbazepine versus carbamazepine monotherapy for partial onset...

Next >>
In Vitro Bactericidal Activity of Iclaprim in Human Plasma